Source: BioPortfolio

Plexcera: Roivant and Plexcera spin out Farber disease biotech Enzyvant

Roivant Sciences and Plexcera Therapeutics have announced the formation of Enzyvant Sciences a new biopharmaceutical

Read full article »
Est. Annual Revenue
$5.0-25M
Est. Employees
1-25
CEO Avatar

CEO

Update CEO

CEO Approval Rating

- -/100